AFFiRiS AG

Alzheimer's

Vaccination
Information
Therapy

Parkinson disease

Information
Press Release

Atherosclerosis

Information
Press Release

Hypertension

Press release

Welcome

AFFiRiS is an innovative, Vienna-based biotechnology company. Using its proprietary AFFITOME® - technology, it is able to develop customised peptide-based vaccines targeting Alzheimer’s disease, Parkinson's disease, atherosclerosis, hypertension and other diseases with unmet medical needs.

AFFiRiS was founded by Dr. Walter Schmidt (CEO) and Dr. Frank Mattner (CSO) in late 2003. Based on its business model and its globally unique expertise, AFFiRiS aims to initiate the clinical testing of a new vaccine against thus-far incurable diseases every 2 to 3 years.

News

AFFiRiS AG: Alzheimer's vaccine AD02 already in clinical phase II

April 23, 2010 : AFFiRiS AG's clinical Alzheimer's vaccine candidate AD02 has already progressed to phase II clinical testing. It may therefore be possible to confirm the efficacy of the vaccine as early as during 2012. more